The
Pharma Strategies
Webinar Series
Managing
Current Challenges to Ensure Future Growth
Hear
industry professionals discuss how to address the challenges every
executive is facing – from reigning in the high costs of
R&D and marketing to declining research productivity, pricing
pressures and regulatory constraints.
A
New Look at
Primary Care
In
2008, the primary care-driven segment of the global pharmaceutical
market will go negative for the first time. Join industry experts
as they explore how pharmaceutical companies can instill a “whole
product” approach to their medications.
Get
FREE replays of these webinars HERE.
|
|
|
A
FREE webinar
Thursday, Nov. 20, 2008 • 12 PM ET / 9 AM PT • 90 minutes
About
the event • Key topics • Who
should attend • Speakers • Benefits
•
Register • About the series
Featuring
Roger
Longman
(moderator)
Managing
Partner / Windhover Information
Publisher / IN
VIVO, Start-Up and
The RPM Report
David
Campbell
Senior Principal
/ SDG Life Sciences, a unit of IMS
Unprecedented
changes in the global healthcare market are altering the focus of all
pharmaceutical companies. Key countries such as China, Brazil,
Mexico, South Korea, India, Turkey and Russia are growing at 12 to 16
percent each year and represent significant opportunities for manufacturers
of all sizes and specialties. IMS estimates that these "pharmerging"
countries will contribute to more than 32 percent of global market growth
by 2012, requiring companies to think — and at times act —
locally and accommodate diverse social norms and medical practices.
The
best results will be achieved when the business acumen of Western companies
is partnered with the social and cultural mores of countries in the
emerging markets. But how can companies determine which approach is
best, and more importantly, formulate discrete strategies that will
drive the greatest returns given geographic and cultural variances?
Is
your company prepared for success in the pharmerging markets?
Moderated by Roger Longman, Windhover Information Managing Partner, this
90-minute, interactive webinar will provide an in-depth review of emerging
market drivers, local differences, and the risks and challenges associated
with commercialization. IMS and industry experts will share their perspectives
on growth opportunities and strategic considerations every company must
assess as they determine whether or not to expand in these markets.
REGISTER
NOW!
So join us, in the
convenience of your own office, for a thought-provoking analysis of
the issues central to your company's success. Grab your team (or several
teams), a conference room at your office, a phone and a computer with
Web access (that last one's optional). No travel required.
Key
discussion highlights include:
- Common
elements of the pharmerging markets
- Cultural
differences that will influence market growth
- Risk
management strategies
- Effectively
marketing products in these countries
Back
to top
Pharma
and biotech senior executives in:
- Business
development
- Portfolio
strategy
- Brand
management
- Strategic
planning
- Other
commercial areas
Back
to top
|
Roger
Longman
Managing
Partner
Windhover Information
Roger
Longman is a Managing Partner at Windhover Information, an Elsevier
company. He has been involved with the health care industry for
more than 20 years.
In 1983, Mr.
Longman joined The Wilkerson Group as a writer covering the pharmaceutical
and biotech industries for IN VIVO: The Business &
Medicine Report. In 1989, Longman along with David
Cassak led a buyout of the Wilkerson Group's publications division,
which they moved to Connecticut and renamed Windhover Information
Inc.
Since then Mr.
Longman and Mr. Cassak have launched several new ventures including:
- Start-Up:
Windhover’s Review of Emerging Medical Ventures;™
-
Strategic Transactions Database,
the industry’s most comprehensive and detailed database
of industry M&A, alliances and financings;
-
The RPM Report: Regulation • Policy • Market Access™,
an analysis of key marketing, strategy and R&D implications
of the changes in Washington at CMS and FDA;
- and a series
of senior-executive conferences in corporate strategy, business
development, R&D, and finance.
In 2004, Windhover
acquired Medtech Insight, an information company covering the medical
device field through a market-leading newsletter, a series of in-depth
market reports, and a number of conferences. In 2008, Windhover
was acquired by Reed Elsevier.
Under Elsevier,
Mr. Longman runs a newly-created business unit that features several
leading publications serving biopharma executives, including IN
VIVO, Start-Up, The
RPM Report and “The Pink Sheet,”
“Pink Sheet Daily” and PharmAsia
News, among others. In addition, the new unit will
oversee biopharmaceutical conferences and partnering events, as
well as and biopharmaceutical content in Windhover’s M&A,
alliance, and financing transactions database.
Over the years,
Mr. Longman has become recognized as one of the leading experts
in biopharmaceutical strategy and dealmaking. He is often asked
to speak at many key industry events organized by important trade
organizations like the Biotechnology Industry Organization (BIO),
investment banks, venture capital firms and leading pharma and biotech
companies. He lectures regularly at several leading universities.
Mr. Longman completed his BA at Cornell University and an MA at
the University of North Carolina at Chapel Hill, and then taught
for three years at the European division of the University of Maryland. |
|
David
Campbell
Senior Principal
SDG Life Sciences, a unit of IMS
David
Campbell is a Senior Principal at SDG Life Sciences, a unit of IMS.
Based in London, he has over 10 years of global industry experience.
Prior
to joining SDG, Mr. Campbell was a partner at Catenion Strategies,
a boutique strategy consulting firm based in Berlin. At Catenion
he led numerous engagements, including a post-merger development
portfolio review for a major pharmaceutical manufacturer, helping
a new entrant in the oncology market to define the late-stage development
program for a key brand that has since become a major player in
the oncology space.
Mr.
Campbell was also chief scientific officer for Etiologics, where
he was a member of the senior management team who led the purchase
of Bayer's pre-clinical respiratory capability. After leaving Etiologics,
he served as an external consultant to AstraZeneca, helping them
to define their discovery medicine strategy for oncology. Before
this, Mr. Campbell was a group leader in genetic technologies at
SmithKline Beecham, and subsequently assumed the role of director
of molecular genetics Europe for the combined GlaxoSmithKline organization.
Towards the end of his tenure at GSK, he led a team responsible
for reviewing and rationalizing the company’s genetics Research
portfolio. Earlier in his career, he led a genetic research group
at the University of Leeds, where the team defined the genetic basis
of a number of disorders such as asthma and anorexia nervosa.
Mr.
Campbell holds a degree in immunology and pharmacology from Strathclyde
University as well as a PhD from Glasgow University.
|
Back
to top 
What does
registration get me?
- One (1) phone line,
for you alone, or around which to gather your team(s). No charge in
the U.S. only.
- One (1) password
to a website on which you'll view presenters’ slides.
- An interactive
Q&A round with speakers: Submit your questions for the speakers
to address.
- The insight you've
come to expect and respect from Windhover and our guest speakers.
What are the
unique benefits of a webinar?
- Convenience
– and lower cost.Your entire team can listen in one room.
No travel required!
- A team
approach. You've often wanted to have everyone on your team
getting the same knowledge and insight you derive from physical conferences.
Now you can.
- Interactivity.
You're remote, but not removed. Our webinars let you ask the important,
burning, controversial questions of our speakers that you'd be able
to pose at a physical conference.
Back
to top
Former
Intel CEO Andrew Grove coined the term “strategic inflection point”
to describe the time when a business is about to experience an irrevocable
change.
After
30 years of remarkable success and consistent growth, the pharmaceutical
sector is at this “inflection point,” and has entered a
period of uncertainty and diminished expectations. Growth has slowed
in major markets, regulatory and pricing structures are more constrained,
and the industry is challenged by increasing generics and a drought
in R&D productivity. The once-clear template for success is now
out of date, and industry leaders are looking for new organizing principles
and a new framework for strategic thinking.
Join
IMS and other industry experts in a webinar series hosted by Roger Longman
of Windhover Information as we explore new growth opportunities in the
pharmaceutical industry – where to play and how to win in an increasingly
competitive, but still highly attractive market
Back
to top
|
